Gail Schwartz

Assistant Professor

If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Gail Schwartz is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 11 Similar Profiles
latanoprost Medicine & Life Sciences
Glaucoma Medicine & Life Sciences
Ocular Hypertension Medicine & Life Sciences
Intraocular Pressure Medicine & Life Sciences
Ophthalmic Solutions Medicine & Life Sciences
Open Angle Glaucoma Medicine & Life Sciences
Timolol Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2017

Clinical outcomes of gamma-irradiated sterile cornea in aqueous drainage device surgery: A multicenter retrospective study

Pan, Q., Jampel, H. D., Ramulu, P., Schwartz, G., Cotter, F., Cute, D., Daoud, Y., Murakami, P. & Stark, W. J., Mar 1 2017, In : Eye (Basingstoke). 31, 3, p. 430-436 7 p.

Research output: Contribution to journalArticle

Multicenter Studies
Retrospective Studies

Adherence and persistence of bimatoprost in prior latanoprost users

Patel, V., Schwartz, G., Landsman-Blumberg, P. B., Lunacsek, O. E. & Wong, W., Nov 1 2016, In : American Journal of Pharmacy Benefits. 8, 6, p. e101-e107

Research output: Contribution to journalArticle


Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: A comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions

Campbell, J. H., Schwartz, G., Labounty, B., Kowalski, J. W. & Patel, V. D., May 14 2014, In : Clinical Ophthalmology. 8, p. 927-935 9 p.

Research output: Contribution to journalArticle

Ophthalmic Solutions
Patient Compliance

An adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%

Wong, W. B., Patel, V. D., Kowalski, J. W. & Schwartz, G., Sep 1 2013, In : Current Medical Research and Opinion. 29, 9, p. 1191-1200 10 p.

Research output: Contribution to journalArticle

Costs and Cost Analysis
Medication Adherence

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: A 12-week, randomised, double-masked trial

Day, D. G., Walters, T. R., Schwartz, G., Mundorf, T. K., Liu, C., Schiffman, R. M. & Bejanian, M., Aug 1 2013, In : British Journal of Ophthalmology. 97, 8, p. 989-993 5 p.

Research output: Contribution to journalArticle

Ocular Hypertension
compound A 12
Ophthalmic Solutions
Intraocular Pressure